目的 探討舒心口服液聯(lián)合鹽酸貝尼地平治療冠心病心絞痛的臨床療效。方法 選取2020年5月—2022年5月在鄭州市第七人民醫(yī)院治療的122例冠心病心絞痛患者，按照隨機數(shù)字表法分為對照組（61例）和治療組（61例）。對照組患者口服鹽酸貝尼地平片，2～4 mg/次，1次/d。在對照組基礎上，治療組口服舒心口服液，20 mL/次，2次/d。兩組治療5 d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀緩解時間，心絞痛發(fā)作頻率，發(fā)作持續(xù)時間，視覺模擬評分法（VAS），血清因子白細胞介素-6（IL-6）、同型半胱氨酸（Hcy）、血管內(nèi)皮細胞黏附因子-1（VCAM-1）和高敏C反應蛋白（hs-CRP）水平，及不良反應情況。結果 治療后，治療組總有效率（98.36%）明顯高于對照組（83.61%，P＜0.05）。治療后，治療組胸痛、胸悶、氣短、乏力緩解時間均明顯短于對照組（P＜0.05）。治療后，兩組的心絞痛發(fā)作頻率、發(fā)作持續(xù)時間、VAS評分，及血清因子IL-6、Hcy、VCAM-1、hs-CRP水平較治療前均明顯下降（P＜0.05），且治療組明顯低于對照組（P＜0.05）。治療后，治療組不良反應發(fā)生率為6.56%，明顯低于對照組（16.39%，P＜0.05）。結論 舒心口服液聯(lián)合貝尼地平治療冠心病心絞痛療效顯著，改善心絞痛癥狀明顯，有效減低炎性反應。

Objective To investigate the efficacy of Shuxin Oral Liquid combined with benidipine in treatment of coronary heart disease angina pectoris. Methods Patient (122 cases) with coronary heart disease angina pectoris in the 7th People's Hospital of Zhengzhou from May 2020 to May 2022 were divided into control group (61 cases) and treatment group (61 cases) according to random number table method. Patient in the control group was po administered with Benidipine Hydrochloride Tablets, 2 — 4 mg/time, once daily. Patient in the treatment group were po administered with Shuxin Oral Liquid on the basis of the control group, 20 mL/time, twice daily. Patient in two groups were treated for 5 d. After treatment, the clinical evaluation was evaluated, and the relief time of symptom, angina attack frequency, attack duration, VAS score, the levels of serum inflammatory factor IL-6, Hcy, VCAM-1 and hs-CRP, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (98.36%) was significantly higher than that of the control group (83.61%, P < 0.05). After treatment, the relief time of chest pain, chest tightness, shortness of breath and fatigue in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the frequency and duration of angina pectoris attack, VAS score, and the levels of serum factors IL-6, Hcy, VCAM-1, and hs-CRP in two groups were significantly lower than those before treatment (P < 0.05), and these indexes in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group was 6.56%, significantly lower than that in the control group (16.39%, P<0.05). Conclusion Shuxin Oral Liquid combined with benidipine has remarkable curative effect in treatment of coronary heart disease angina pectoris, obvious improvement of angina pectoris symptoms and effective reduction of inflammatory reaction.

R972

河南省醫(yī)學科技攻關計劃項目（LHGJ20210754）